Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure
| Autor: | Tomohito Mizuno, Motonobu Nakamura, Masaomi Nangaku, Hiroyuki Tsukada, Nobuhiko Satoh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Nephrology
Arteriovenous grafts medicine.medical_specialty Graft failure Urology medicine.medical_treatment 030232 urology & nephrology Vascular access Arteriovenous fistula Prevention of vascular access failure 030204 cardiovascular system & hematology Controlled studies lcsh:RC870-923 03 medical and health sciences 0302 clinical medicine Internal medicine medicine In patient Transplantation business.industry Prophylactic drugs medicine.disease lcsh:Diseases of the genitourinary system. Urology Vascular access failure Hemodialysis business |
| Zdroj: | Renal Replacement Therapy, Vol 5, Iss 1, Pp 1-13 (2019) |
| ISSN: | 2059-1381 |
| DOI: | 10.1186/s41100-019-0210-2 |
| Popis: | Vascular access failure (VAF) is a critical problem in patients undergoing hemodialysis (HD). Importantly, VAF impairs the quality of life in patients undergoing HD while imposing high medical costs. A variety of strategies (e.g., endovascular therapy and surgical reconstruction) for treating VAF have been established. However, strategies for preventing VAF are scarce. In this review, we summarized the available literatures regarding the prevention of VAF in patients undergoing HD with a focus on arteriovenous fistulas and arteriovenous grafts. This review proposes the following three aspects for developing strategies for preventing VAF: (i) early identification of risk factors of VAF (e.g., preoperative vascular conditions, age, sex, ethnicity, and clinical backgrounds), (ii) prophylactic drugs to reduce the risk of VAF, and (iii) early VAF detection through monitoring and surveillance of vascular access, particularly at frequent stenotic sites. A few prophylactic drugs may effectively prevent VAF based on the patient’s clinical background. A few prophylactic drugs may effectively prevent VAF based on the patient’s clinical background; however, currently, there is no strong evidence on the efficacy of these drugs in reducing the incidence of VAF. Thus, additional large, randomized controlled studies are warranted to establish effective strategies for preventing VAF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink